| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal. New formulation of an established medicine which has similar costs per patient. |
|
Medicine details |
|
| Medicine name | apomorphine hydrochloride (Kynmobi®) |
| Formulation | 10 mg, 15 mg, 20 mg, 25 mg and 30 mg Sublingual films |
| Reference number | 2749 |
| Indication | Intermittent treatment of “OFF” episodes in adult patients with Parkinson's disease (PD) which are not sufficiently controlled by oral anti-Parkinson medication. |
| Company | Bial Bial - Portela & Cª, S.A. |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 18/09/2025 |